… As dapagliflozin is a highly selective SGLT2 inhibitor, which may affect glucose, insulin,
and lipid metabolism, we evaluated systemic blood glucose, blood lipid, and insulin level, …

… dapagliflozin was mainly attributable to a 30% reduction in hospitalizations and urgent heart
failure … , were similar to the known risks of the medicines in the SGLT2 inhibitor class. In the …

… Failure) trial, which included 4744 patients with HFrEF and showed that treatment with the
SGLT2 inhibitor dapagliflozin, … in cardiovascular death and heart failure hospitalization. We …

… cardiac and all-cause mortality of ARNI and dapagliflozin combination therapy against ARNI
monotherapy in patients … Empagliflozin is another SGLT2 inhibitor that has been shown to …

… We observed a significant decrease in NT-proBNP, even though none of the subjects in
this study had a history of heart failure. Even a moderately increased level of NT-proBNP has …

… spectrum for the SGLT2 inhibitor empagliflozin among those with HF and EF >40%. Previous
safety by age analysis of dapagliflozin in patients with heart failure with reduced ejection …

… transition in the aetiology of heart failure (HF) with reduced … and rheumatic valvular disease
to coronary artery disease. Thus, … with SGLT2 inhibition may suggest more benefit in patients …

… of dapagliflozin in HFrEF and heart failure with mildly reduced ejection fraction (HFmrEF)/heart
failure … access to SGLT2 inhibitor therapy for patients with heart failure around the world. …

… The purpose of this study was to investigate clinical outcomes and response to dapagliflozin
in patients with HF with mildly reduced or preserved left ventricular ejection fraction (LVEF) …

… On May 5, 2020, dapagliflozin became the first SGLT2 inhibitor to receive approval from
the US Food and Drug Administration (FDA) for the treatment of HFrEF, including among …